• PharmaCyte Biotech will implement a 1-for-19 reverse stock split effective at 4:01 p.m. Eastern Time on November 12, 2026.
• Split-adjusted trading begins November 13, 2026, on the Nasdaq Capital Market under the existing ticker PMCB.
• The consolidation aims to restore compliance with Nasdaq's minimum bid price requirement.
• Outstanding common shares will fall from approximately 10,755,649 to 566,087; authorized shares will remain unchanged.
• No fractional shares will be issued; holders will receive cash based on the split-adjusted November 12, 2026, closing price.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-008705), on November 13, 2026, and is solely responsible for the information contained therein.